Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor In a JAMA Clinical Evidence Synopsis, Dr Storebø and colleagues1 summarized their previous Cochrane review2 on methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents. The original Cochrane review was flawed in both its methods and interpretation.3 We provide 2 examples.
Romanos M, Reif A, Banaschewski T. Methylphenidate for Attention-Deficit/Hyperactivity Disorder. JAMA. 2016;316(9):994-995. doi:10.1001/jama.2016.10279